Results 31 to 40 of about 17,831 (181)

Gastrointestinal Bleeding: a Cardiologist's Point of View

open access: yesРациональная фармакотерапия в кардиологии, 2021
Oral anticoagulant therapy is widely used in different patients for the prevention and treatment of thromboembolic events: in atrial fibrillation, deep vein thrombosis/pulmonary embolism, acute coronary syndrome, in the early postoperative period after ...
O. V. Averkov, L. N. Mishchenko
doaj   +1 more source

CRASH-2 (Clinical Randomisation of an Antifibrinolytic in Significant Haemorrhage) intracranial bleeding study: the effect of tranexamic acid in traumatic brain injury - a nested, randomised, placebo-controlled trial [PDF]

open access: yes, 2012
Background: Tranexamic acid (TXA) has been shown to reduce blood loss in surgical patients and the risk of death in patients with traumatic bleeding, with no apparent increase in vascular occlusive events.
Wardlaw, J   +22 more
core   +1 more source

Spectrum of thrombotic complications and their outcomes in Chinese children with primary nephrotic syndrome

open access: yesItalian Journal of Pediatrics, 2020
Background Thromboembolism is a life-threatening, limb-threatening or organ-threatening complication that occurs in patients with primary nephrotic syndrome (NS). There are few studies on the spectrum, complications and outcomes of thrombosis in children
Yan-Li Lv   +10 more
doaj   +1 more source

Prevalence of selected bleeding and thrombotic events in persons with hemophilia versus the general population: A scoping review [PDF]

open access: yes, 2023
Life expectancy for persons with hemophilia has increased over recent decades due to advances in treatment practice and patient care. Those with hemophilia are now more likely to be affected by conditions associated with aging, such as myocardial ...
Hardesty, Brandon M.   +3 more
core   +1 more source

Safely Treating a Pulmonary Embolism in a Patient With Hereditary Hemorrhagic Telangiectasia: A Case Report. [PDF]

open access: yesClin Case Rep
ABSTRACT Hereditary Hemorrhagic Telangiectasia (HHT) is a rare autosomal dominant bleeding disorder. The incidence of venous thromboembolisms among HHT patients is significantly greater than the general population. However, providing therapeutic anticoagulation in patients with an increased propensity for bleeding creates a clinical dilemma.
Carfagnini C, Kandula M.
europepmc   +2 more sources

A Nomogram Model for Predicting Prognosis in Spontaneous Intracerebral Hemorrhage Patients

open access: yesJournal of Integrative Neuroscience, 2023
Objectives: Intracranial hemorrhage is the second most common stroke subtype following ischemic stroke and usually induces high mortality and disability. Here, we conducted a retrospective study to establish a nomogram clinical prediction model. Methods:
Yunjie Li   +4 more
doaj   +1 more source

Letter to the Editor: Deep venous thrombosis and pulmonary embolism

open access: yes, 2015
TO THE EDITOR: It is with great interest that we have read the clinical article by Rolston et al. (Rolston JD, Han SJ, Bloch O, et al: What clinical factors predict the incidence of deep venous thrombosis and pulmonary embolism in neurosurgical patients?
Berghauser Pont, Lotte M.E.   +2 more
core   +1 more source

Direct oral anticoagulants vs. low-molecular-weight heparin for pulmonary embolism in patients with glioblastoma

open access: yes, 2021
Glioblastoma (GBM) is a cancer type with high thrombogenic potential and GBM patients are therefore at a particularly high risk for thrombotic events.
Voß, Martin   +13 more
core   +1 more source

Multiple cerebral infarction diagnosed as Eosinophilic Granulomatosis with Polyangiitis by autopsy

open access: yesBMC Neurology, 2019
Background Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare systemic vasculitis of unknown cause involving the brain and accompanied by prominent eosinophilia.
Kenichiro Hira   +9 more
doaj   +1 more source

Edoxaban: an update on the new oral direct factor Xa inhibitor. [PDF]

open access: yes, 2014
Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with ...
Camm, AJ   +3 more
core   +1 more source

Home - About - Disclaimer - Privacy